Experience with FLT3 Inhibitor Midostaurin in Newly Diagnosed Acute Myeloid Leukemia Patients

Introduction With the introduction of FLT3 inhibitors in recent years, the presence of FLT3 mutation in newly diagnosed acute myeloid leukemia (AML) patients has become more important. it was observed that the addition of Midostaurin to remission induction and consolidation chemotherapy, brought a 2...

Full description

Bibliographic Details
Published in:Turkish Journal of Internal Medicine
Main Authors: Mehmet Baysal, Nihan Alkis, Serap Baysal
Format: Article
Language:English
Published: Nizameddin KOCA 2021-03-01
Subjects:
Online Access:https://dergipark.org.tr/tr/download/article-file/1552683